Featured news | Nanologica

Nanologica Receives Order for Silica for Preparative Chromatography from US Customer

3 October, 2022

Nanologica AB (publ) has received an order for the company’s silica for preparative chromatography to a value of approximately TSEK 230. The order comes from a customer in the North American market. During 2022, Nanologica has completed the up-scaling to large-scale production of the company’s commercial silica for preparative chromatography, NLAB Saga®. This order is a direct consequence of the company now being able to deliver the volumes of silica required for customers to be

CEO Comment in Connection with the Preferential Rights Issue 2022

20 September, 2022

In 2022, Nanologica has taken important steps forward in the chromatography business area. We have scaled up the production of our commercial silica for preparative chromatography, NLAB Saga®, to tonal scale, and we have sold the first products in preparative chromatography, as well as taken orders for NLAB Saga® for production-scale evaluation from one of the world’s largest insulin manufacturers. The fact that we now have products from our large-scale production means that we can

Nanologicas vd Andreas Bhagwani presenterar med anledning av pågående företrädesemission

20 September, 2022

Den 27 september 2022, kl 12.00 bjuder Nanologica in till en presentation och frågestund med Nanologicas vd Andreas Bhagwani hos Infront Direkt Studios, Kungsgatan 33, 115 56 Stockholm. Anmälan sker till ir@nanologica.com. Presentationen kommer även att sändas live via länk:

Nanologica Publishes Prospectus in Connection with Preferential Rights Issue

20 September, 2022

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, HONG KONG, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The Board of Directors of Nanologica AB (publ) (“Nanologica” or the Company”) announced on 23 August 2022 that the Board of Directors has resolved

Nanologica Receives Order for Silica for Preparative Chromatography

31 August, 2022

Nanologica AB (publ) has taken an order for the company’s silica for preparative chromatography at a value of approximately MSEK 1.3. The order comes from Nanologica’s partner in China, Yunbo Technology (Beijing) Co. Ltd. In July 2019, Nanologica signed an agreement with Chinese Yunbo Technology for the supply of silica for preparative chromatography worth approximately MUSD 14 (currently equivalent to approximately MSEK 150), between 2021 and 2026. The order that has now been placed is

Nanologica AB presenterar på Erik Penser Banks bolagsdag 24 augusti

23 August, 2022

Vd Andreas Bhagwani presenterar Nanologica den 24 augusti kl 13.05 på Erik Penser Banks bolagsdag.

About us

Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances. Nanologica’s offering enables efficient and scalable production of drug substances, with particular strength within complex molecules and peptide-based drugs, such as treatments for diabetes and obesity. The company positions itself as a long-term partner to the pharmaceutical industry, with the goal of enabling more patients around the world to have access to life-saving treatments and cost-effective medicines. The Group has about 70 employees and is headquartered in Södertälje. Nanologica’s share (ticker NICA) has been listed on Nasdaq Stockholm’s main market since 2022.